Skip to main content
Erschienen in: Esophagus 2/2011

01.06.2011 | Original Article

Induction chemoradiotherapy followed by esophagectomy for advanced squamous cell carcinoma of the esophagus

verfasst von: Tsutomu Nakamura, Masaho Ota, Takeshi Ohki, Takuya Sato, Yuji Shirai, Masakazu Yamamoto, Norio Mitsuhashi

Erschienen in: Esophagus | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemoradiotherapy (CRT) has been performed for locally advanced thoracic esophageal carcinoma. To evaluate the outcome of induction CRT followed by esophagectomy, we compared it with that of definitive CRT.

Patients

Of 121 patients with T3–T4 squamous cell carcinoma who received CRT, 39 patients received induction CRT (total, 30–50 Gy) followed by esophagectomy and 82 patients received definitive CRT (>50 Gy), including the 30 patients who underwent salvage esophagectomy.

Methods

We reviewed the data of response to CRT, outcome of esophagectomy, survival, and recurrence sites.

Results

Pathological findings of response to induction CRT revealed pathological complete response (pCR) (grade 3) in 9 patients (23%), partial response (pPR) (grade 2) in 17 patients (45%), and no response (pSD) (grade 1/0) in 13 patients (33%). Clinical response evaluation of definitive CRT showed that 31 (38%) patients achieved CR, 49 incomplete response/stable disease, and 2 progressive disease. Although the induction group was significantly superior to the definitive group in terms of local progression survival (P = 0.0063), no difference was shown in overall survival between the two groups. Salvage esophagectomy for locoregional recurrence significantly improved survival after definitive CRT. There was no difference in postoperative survival between the patients who underwent esophagectomy after induction CRT and those who underwent salvage esophagectomy. Long-term survivors in the definitive CRT group frequently suffered from cardiopulmonary diseases or recurrence.

Conclusions

Induction CRT followed by esophagectomy showed superior results compared with definitive CRT in local progression but no difference in overall survival.
Literatur
1.
Zurück zum Zitat Walsh TN, Nooman N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;325:462–7.CrossRef Walsh TN, Nooman N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;325:462–7.CrossRef
2.
Zurück zum Zitat Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GMM, Murthy SC, et al. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gatroesophageal junction. Am J Clin Oncol. 2007;30:172–80.PubMedCrossRef Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GMM, Murthy SC, et al. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gatroesophageal junction. Am J Clin Oncol. 2007;30:172–80.PubMedCrossRef
3.
Zurück zum Zitat Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef
4.
Zurück zum Zitat Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ, Clifton J. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257–64.PubMedCrossRef Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ, Clifton J. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257–64.PubMedCrossRef
5.
Zurück zum Zitat El Nakadi I, Van Laethem JL, Houben JJ, Gay F, Closset J, Van Houtte P, Danhier S, Limbosch JM, Lambilliotte JP, Gelin M. Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease. World J Surg. 2002;26:72–8.PubMedCrossRef El Nakadi I, Van Laethem JL, Houben JJ, Gay F, Closset J, Van Houtte P, Danhier S, Limbosch JM, Lambilliotte JP, Gelin M. Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease. World J Surg. 2002;26:72–8.PubMedCrossRef
6.
Zurück zum Zitat Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for respectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15:947–54.PubMedCrossRef Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for respectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15:947–54.PubMedCrossRef
7.
Zurück zum Zitat Stahl M, Sttuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.PubMedCrossRef Stahl M, Sttuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.PubMedCrossRef
8.
Zurück zum Zitat Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD9102. J Clin Oncol. 2007;25:1160–8.PubMedCrossRef Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD9102. J Clin Oncol. 2007;25:1160–8.PubMedCrossRef
9.
Zurück zum Zitat Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Matono S, Mori N, Shirouzu K, Yamana H, Suzuki G, Hayabuchi N, Matsui M. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospected nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–31.PubMedCrossRef Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Matono S, Mori N, Shirouzu K, Yamana H, Suzuki G, Hayabuchi N, Matsui M. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospected nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–31.PubMedCrossRef
10.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMedCrossRef Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMedCrossRef
11.
Zurück zum Zitat Nakamura T, Hayashi K, Ota M, Eguchi R, Ide H, Takasaki K, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188:261–6.PubMedCrossRef Nakamura T, Hayashi K, Ota M, Eguchi R, Ide H, Takasaki K, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188:261–6.PubMedCrossRef
12.
Zurück zum Zitat Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardivasc Surg. 2009;137:49–54.CrossRef Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardivasc Surg. 2009;137:49–54.CrossRef
13.
Zurück zum Zitat Sobin LH, Wittekid C. TNM classification of malignant tumors. International Union against cancer. 5th ed. New York: Wiley; 1997. Sobin LH, Wittekid C. TNM classification of malignant tumors. International Union against cancer. 5th ed. New York: Wiley; 1997.
14.
Zurück zum Zitat Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the thoracic esophagus (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.PubMedCrossRef Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the thoracic esophagus (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.PubMedCrossRef
15.
Zurück zum Zitat Takagawa R, Kunisaki C, Makino H, Kosaka T, Ono H, Akiyama H, et al. Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus. Dis Esophagus. 2008;22:482–9.CrossRef Takagawa R, Kunisaki C, Makino H, Kosaka T, Ono H, Akiyama H, et al. Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus. Dis Esophagus. 2008;22:482–9.CrossRef
16.
Zurück zum Zitat Ishikura S, Ohtsu A, Shirao K, Muro K, Kagami Y, Nihei K, et al. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908). Esophagus. 2005;2:133–7.CrossRef Ishikura S, Ohtsu A, Shirao K, Muro K, Kagami Y, Nihei K, et al. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908). Esophagus. 2005;2:133–7.CrossRef
17.
Zurück zum Zitat Japan Esophageal Society. Japanese classification of esophageal cancer, 10th ed. (part II and III). Esophagus. 2009;6:71–94. Japan Esophageal Society. Japanese classification of esophageal cancer, 10th ed. (part II and III). Esophagus. 2009;6:71–94.
18.
Zurück zum Zitat Yano M, Tsujinaka T, Shiozaki H, Inoue M, Doki Y, Yamamoto M, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70:25–32.PubMedCrossRef Yano M, Tsujinaka T, Shiozaki H, Inoue M, Doki Y, Yamamoto M, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70:25–32.PubMedCrossRef
19.
Zurück zum Zitat Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 2009;33:1002–9.PubMedCrossRef Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 2009;33:1002–9.PubMedCrossRef
20.
Zurück zum Zitat De Manzoni G, Pedrazzani C, Laterza E, Pasini F, Grandinetti A, Bernini M, Ruzzenente A, Zerman G, Tomezzoli A, Cordiano C. Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg. 2005;80:1176–84.PubMedCrossRef De Manzoni G, Pedrazzani C, Laterza E, Pasini F, Grandinetti A, Bernini M, Ruzzenente A, Zerman G, Tomezzoli A, Cordiano C. Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg. 2005;80:1176–84.PubMedCrossRef
21.
Zurück zum Zitat Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, and surgery compared with surgery alone for esophageal cancer: CALGB9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRef Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, and surgery compared with surgery alone for esophageal cancer: CALGB9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRef
22.
Zurück zum Zitat Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. J Clin Oncol. 2003;21:2697–702.PubMedCrossRef Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. J Clin Oncol. 2003;21:2697–702.PubMedCrossRef
Metadaten
Titel
Induction chemoradiotherapy followed by esophagectomy for advanced squamous cell carcinoma of the esophagus
verfasst von
Tsutomu Nakamura
Masaho Ota
Takeshi Ohki
Takuya Sato
Yuji Shirai
Masakazu Yamamoto
Norio Mitsuhashi
Publikationsdatum
01.06.2011
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 2/2011
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-011-0268-6

Weitere Artikel der Ausgabe 2/2011

Esophagus 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.